Category: MS Research Study and Reports

EDSS ‘0’ is not normal: Multiple sclerosis disease burden below the clinical threshold

2022 Jul 13;13524585221108297 –   doi: 10.1177/13524585221108297. Online ahead of print.  Stephen C Krieger 1, Ali Antoine 1, James F Sumowski 1 PMID: 35832024   DOI: 10.1177/13524585221108297 #MS disability…

Stuart Schlossman

Health Care Utilization, Prodromal Symptoms Prior to Pediatric-Onset MS

 By Sheila Jacobs – June 7, 2022 Neurologic complaints included headache, sensory symptoms, visual symptoms, and motor symptoms in the 2…

Stuart Schlossman

Diroximel Fumarate for Relapsing MS: How Does It Affect Clinical Outcomes?

 June 8, 2022 – Mary Stroka The most frequent AEs were flushing (32.3%), nasopharyngitis (24.6%), and MS relapse during treatment with…

Stuart Schlossman

Ocrelizumab Reduces Thalamic Volume Loss

Ocrelizumab Reduces Thalamic Volume Loss, – Cenobamate Shines in C017 Study, Trial of LRRK2 Inhibitor BIIB122 Commences Using the phase 3…

Stuart Schlossman

Media Update: Patient enrollment of phase III tolebrutinib trials paused in the U.S.

 Paris, June 30, 2022. The U.S. Food and Drug Administration (FDA) has placed Phase 3 studies of tolebrutinib in multiple sclerosis (MS)…

Stuart Schlossman

Brain age as a surrogate marker for cognitive performance in multiple sclerosis

Information provided by:  Gavin Giovannoni, aka Prof G  @GavinGiovannoni Are you ready for some hard-to-process information about the impact of…

Stuart Schlossman

Multiple Sclerosis DMT Waste Is STARTLING, New Study Shows (View the photo with the waste build-up)

June 22, 2022  — by: Alicia Bigica More than $5.2 million in new, unused DMTs were collected from patients with…

Stuart Schlossman

Beer Consumption May Be Linked to MS Risk: Meta-analysis

  Alcohol intake is not significantly associated with an increased risk of developing multiple sclerosis (MS), but specifically drinking beer may elevate…

Stuart Schlossman

Research Opportunity for Individuals Diagnosed with Relapsing-Remitting Multiple Sclerosis! – A study to evaluate the effects of three diets

June 2022  Wahls UIHC Clinical Research is recruiting for a new study! You are invited to participate in a research study…

Stuart Schlossman

Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers – PubMed

 Monica Margoni 1 2, Paolo Preziosa 1 3, Paola Tortorella 4, Massimo Filippi 1 3 5 6 7, Maria A Rocca 8 9 10 Affiliations expand PMID: 35668317   DOI: 10.1007/s13311-022-01252-5 Abstract Multiple sclerosis (MS) is a chronic inflammatory, demyelinating,…

Stuart Schlossman

Categories

Latest Blog Posts